RxSight (NASDAQ:RXST) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

RxSight (NASDAQ:RXST) announced its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07), FiscalAI reports. The company had revenue of $30.89 million for the quarter, compared to analyst estimates of $29.75 million. RxSight had a negative return on equity of 14.05% and a negative net margin of 28.96%.The firm’s quarterly revenue was down 18.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.03) earnings per share.

Here are the key takeaways from RxSight’s conference call:

• Management says LAL utilization has stabilized for a third consecutive quarter and their customer re‑engagement programs are showing early, measurable improvements in practices that receive targeted clinical reviews and workflow support.
• Q1 sales were $30.9 million (down 18% YoY), GAAP net loss was $15.9 million, and only 20 LDDs were sold in the quarter, highlighting near‑term revenue and profitability pressure.
• The company reiterated full‑year 2026 revenue guidance of $120M–$135M and gross margin guidance of 70%–72%, but expects a margin step‑down as higher‑cost 2025 inventory is absorbed and plans OpEx at the high end of the prior $150M–$160M range to fund commercial expansion.
• International expansion is progressing (recent approval in New Zealand and activity across Europe, Korea and Australia); management expects modest 2026 contribution with the international business becoming a more meaningful growth driver in 2027 and beyond.
• RxSight plans product enhancements (PMA supplements in process) aimed at simplifying LAL implementation, reducing required LDD treatments, and extending correction range, which management says should lower adoption friction and support longer‑term growth.

RxSight Trading Down 6.6%

Shares of RXST traded down $0.48 on Wednesday, reaching $6.78. The company’s stock had a trading volume of 1,396,729 shares, compared to its average volume of 621,828. The stock has a market capitalization of $280.69 million, a PE ratio of -7.14 and a beta of 1.24. The firm has a fifty day moving average of $7.17 and a 200-day moving average of $8.95. RxSight has a twelve month low of $5.90 and a twelve month high of $16.74.

Hedge Funds Weigh In On RxSight

Hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in shares of RxSight during the 2nd quarter worth approximately $28,000. Larson Financial Group LLC grew its stake in RxSight by 110.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after buying an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in RxSight by 440.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after buying an additional 3,063 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in RxSight by 156.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock valued at $72,000 after buying an additional 3,398 shares in the last quarter. Finally, Aquatic Capital Management LLC boosted its holdings in RxSight by 200.3% in the 3rd quarter. Aquatic Capital Management LLC now owns 11,043 shares of the company’s stock valued at $99,000 after purchasing an additional 7,366 shares during the period. Institutional investors own 78.78% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on RXST. William Blair began coverage on shares of RxSight in a research note on Friday, January 30th. They issued a “market perform” rating on the stock. UBS Group upped their price target on shares of RxSight from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Thursday, February 26th. Wolfe Research upgraded shares of RxSight to an “outperform” rating in a report on Friday, January 30th. Piper Sandler dropped their price objective on shares of RxSight from $11.00 to $10.00 and set a “neutral” rating on the stock in a report on Thursday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $13.00 price objective on shares of RxSight in a report on Thursday, February 26th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $9.78.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.